Skip to main content

Medicine Matters oncology

Notably, combination therapies are an important part of the future of advanced disease treatment. One phase I trial is investigating the combination of HDAC inhibitor romidepsin with doxorubicin chemotherapy for patients with relapsed or refractory CTCL. Another phase II trial is investigating the combination of talimogene laherparepvec (T-VEC, Imlygic™) with the PD-1 inhibitor nivolumab. T-VEC is a genetically engineered oncolytic herpes virus with a favorable safety profile and is thought to promote immune responses, making it a good candidate for combination therapy with other immunotherapies [29] (Table 2).